
Please try another search
Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laboratory, LAPEC, MEDiS Unit, M2iSH, Clermont-Ferrand Clinical Investigation Center, ADECAL, and IFREMER. Valbiotis SA was incorporated in 2014 and is based in Périgny, France.
Name | Age | Since | Title |
---|---|---|---|
Agnes Tixier | 56 | 2019 | Independent Member of Supervisory Board |
Jean Zetlaoui | - | 2017 | Independent Member of Supervisory Board |
Thierry Maugard | - | - | Member of Scientific & Medical Board |
Jean-Marie Bard | - | - | Member of Scientific & Medical Board |
Laurent Levy | 52 | 2017 | Independent Chairman of Supervisory Board |
Bruno Guigas | - | - | Member of Scientific & Medical Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review